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Abstract. Cholecystokinin (CCK) and gastrin stimulate
growth of pancreatic cancer. Although down-regulation of
gastrin inhibits growth of pancreatic cancer, the contribution
of endogenous CCK to tumor growth is unknown. The
purpose of this study was to evaluate the role of endogenous
CCK on autocrine growth of pancreatic cancer. Pancreatic
cancer cell lines were analyzed for CCK mRNA and peptide
expression by real-time RT-PCR and radioimmunoassay,
respectively. The effect of endogenous CCK on growth was
evaluated by treating cancer cells with CCK neutralizing
antibodies and by down-regulating CCK mRNA by RNAi.
Wild-type pancreatic cancer cells expressed significantly
lower CCK mRNA and peptide levels than gastrin. Neither
treatment of pancreatic cancer cells with CCK antibodies nor
the down-regulation of CCK mRNA and peptide by shRNAs
altered growth in vitro or in vivo. Conversely, when gastrin
mRNA expression was down-regulated, the same cells failed
to produce tumors in spite of having sustained levels of
endogenous CCK. Pancreatic cancer cells produce CCK and
gastrin; however, the autocrine production of gastrin is more
important for stimulating tumor growth.
Introduction
Growth factors which regulate cancer cell function have
become prime targets for cancer therapy, including pancreatic
cancer. One newer method for targeting cancers has included
novel therapeutics based on RNA interference (RNAi)
toward growth factors; (1) however, validated RNAi targets
must first be designed and tested in vitro and in animal
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models. The gastrointestinal peptides CCK and gastrin are
potential targets for cancer therapeutics since both of these
peptides have been shown to stimulate growth of this malignancy (2,3) through the CCK2 (or CCK-B) receptor with
gastrin having a greater affinity than CCK for this receptor in
malignant cells (4-6).
The role of gastrin in autocrine growth regulation of
pancreatic cancer has been established (7). Normal human
and porcine pancreas contain small amounts of bioactive
amidated gastrins in the fetal pancreas (8,9) however, after
birth, gastrin immunoreactivity is found primarily located in
the G-cells of the gastric antrum and not in the adult pancreas
(10). In contrast, gastrin immunoreactivity has been identified
in human pancreatic cancer cells and tissues (3,7,11) suggesting
the re-expression or an over-expression of this peptide in the
malignant state and a role in the development of this cancer
(12). The fully processed form of gastrin, gastrin-17, was
detected in cultured pancreatic cancer cells and their growth
medium indicating that this peptide was secreted from the
cells and in surgically removed pancreatic cancer specimens
from patients by immunohistochemistry and radioimmunoassay (RIA) (7,9,13). Down-regulation of gastrin gene expression by RNAi decreases tumor gastrin peptide production,
tumor growth and metastases (14).
Although exogenous administration of CCK to pancreatic
cancer cells also stimulates growth (2,15) the role of CCK as
an autocrine growth regulator in pancreatic cancer has not
been examined. Goetze and colleagues (16) assessed human
pancreatic cancer surgical specimens for gastrin and CCK
peptide and mRNA expression by radioimmunoassay and
RT-PCR, respectively. Although this group found high levels
of ·-amidated gastrins and its precursor forms in 74% of the
pancreatic tumor specimens, CCK was not found (16). In
contrast, Tamiolakis and coworkers (17) reported CCK
immunoreactivity in 10 out of 15 surgical specimens with the
CCK-positive cells identified in the duct-like structures of the
pancreatic tumors. Therefore, the literature has conflicting
reports on whether pancreatic cancer cells synthesize CCK
and whether this peptide serves a physiological role in the
stimulation of cancer cell growth.
In the current investigation, we evaluated the quantitative
expression and function of autocrine CCK in human pancreatic
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cancer cells. CCK mRNA levels in pancreatic cancer cells
were measured by real-time RT-PCR and CCK peptide levels
were quantified by RIA. By using RNA interference and
antisense technologies that specifically down-regulate either
CCK or gastrin mRNA expression, the role of these peptides
on cancer cell growth was studied.
Materials and methods
Cell lines. The human pancreatic cancer cell lines used in these
experiments were purchased from the ATCC (Rockville,
MD), and were maintained in the appropriate media: DMEM
with 10% FBS for PANC-1 and MIA PaCa-2, Iscove's with
20% FBS for Capan-1 and RPMI-1640 with 10% FBS for
BxPC-3 and AsPC-1.
Measurement of CCK, gastrin, CCK1 receptor and CCK2
receptor mRNA by RT-PCR in pancreatic cancer cells. RNA
was extracted from wild-type human ductal pancreatic cancer
cells using RNeasy kits (Qiagen, Valencia, CA). For real-time
RT-PCR, RNA was quantified on an RNA 6000 Nanochip
using the Agilent Bioanalyzer 2100. First-strand cDNA was
produced from 1.0 μg of total RNA using random hexamer primers and a SuperScript III reverse transcription kit (Invitrogen,
Carlsbad, CA). cDNA (100 ng per reaction) was analyzed
using TaqMan Gene expression assays for CCK (assay ID
Hs00174937_m1), gastrin (assay ID Hs00174945_m1), CCK1
receptor (assay ID Hs00167891_m1), and CCK2 receptor
(assay ID Hs00176123_m1) with cyclophilin A (assay ID
Hs99999904_m1) as the internal control (Applied Biosystems,
Foster City, CA). To exclude the possibility of genomic
DNA contamination, control reactions with no cDNA template
were performed. PCR amplification and analysis were done
with the Applied Biosystems Sequence Detection System
7700 using the relative quantification (ddCt) plate setup. RNA
from wild-type PANC-1 cells was used as an expression
calibrator for each target.
Detection of CCK peptide by immunocytochemistry in
pancreatic cancer cells. BxPC-3 cells were plated onto
22-mm2 round glass coverslips and grown in complete media
for 36-48 h. After the media were removed, the cells were
washed and fixed in 2% formaldehyde for 15 min at 4˚C.
Cells were rinsed twice with 1X phosphate-buffered saline
(PBS), permeabilized with 0.25% Triton X-100 for 10 min
followed by incubation in 100 mM glycine in PBS for 5 min
at room temperature and an additional 1X PBS rinse. Nonspecific antibody binding was blocked with 5% normal goat
serum in PBS for 1 h at room temperature. Cells were
incubated in the same buffer containing a rabbit polyclonal
anti-CCK antibody (C2581, Sigma, St. Louis, MO) at a titer
of 1:5,000 overnight at 4˚C. After 3 washes in PBS, the cells
were incubated in PBS containing 2% normal goat serum and
a goat anti-rabbit Alexa Fluor 568-labeled secondary antibody
(Invitrogen) (1:2,000) for 2 h at room temperature. The slides
were washed 2 times with PBS for 30 min each and mounted
on slides using DAPI medium for visualization of nuclei. The
negative control was wild-type BxPC-3 cells incubated with
secondary antibody alone (1:2,000). Immunofluorescent
staining was visualized and photographed using a Leica TCS

SP2 AOBS confocal microscope using 63X objective at the
appropriate laser settings.
In vitro growth studies with selective peptides and anti-CCK
antibodies. CCK-8 (sulfated, MW 1143.29) and gastrin-17
(sulfated, MW 2178.30) were purchased from Peninsula
Laboratories (San Carlos, CA). Pancreatic cancer cells were
adapted to grow in serum-free media, and growth rates were
then evaluated in the presence of exogenously administered gastrin or CCK. Cells (1x105) were plated in each well
of a 12-well plate and treated with various concentrations
(10-11-10-7 M) of gastrin or CCK (6 wells for each concentration). Fresh media with or without the indicated peptide
was added daily and viable cells were counted by hemacytometer after 6 days of treatment.
A series of experiments were designed to examine the
effect of decreasing the levels of CCK peptide secreted from
pancreatic cancer cells into growth media. Two different CCK
antibodies against either fully processed CCK or proCCK
were used. The first antibody, Ab89009, was a polyclonal
rabbit antibody raised against the non-processed N-terminus
sequence (62-71) of human proCCK and was a gift of
Professor Jens Rehfeld (18). This antibody has no detectable
cross-reactivity with gastrin or fully processed CCK-8 (18).
The second polyclonal antibody, C2581, was purchased from
Sigma-Aldrich, and was produced using as an immunogen
the synthetic-sulfated cholecystokinin (26-33) amide (sulfated
CCK-8), conjugated to KLH. Low cross reactivity is observed
with gastrin-17 (0.2%) and gastrin-34 (1.0%). Both of these
CCK antibodies functionally neutralize the capacity of CCK
to bind to CCK receptors.
CCK antibody experiments were performed with both
BxPC-3 cells (which express moderate-CCK mRNA levels
and high-gastrin mRNA levels) and PANC-1 cells (which
express high-CCK mRNA and low-gastrin mRNA levels).
BxPC-3 cells or PANC-1 (4x104) were plated in 12-well
tissue culture dishes and grown in serum-free media on day 0.
Cells were treated in different experiments with either the
proCCK antibody Ab89009 (BxPC-3) or the fully-processed
antibody CCK AbC2581 (BxPC-3 and PANC-1) in dilutions
ranging from 1:5,000-1:500. Control cells were treated with
either a non-immune IgG (Sigma) as a non-specific antibody
control, or media only. Cells were treated at two-time intervals:
the first at 24 h after plating and the second at 96 h after
plating. After 7 days of growth, cells were harvested and
viable cells counted using the trypan blue exclusion technique.
Down-regulation of CCK with RNAi and antisense transfection.
BxPC-3 cells were independently transfected with one of two
shRNA (short hairpin RNA) constructs targeting independent, non-overlapping regions of human CCK mRNA.
shRNA site selection was based upon open mRNA secondary
structure and low off-target effects. The shRNA target
sequences used are shown in Table I and started at nucleotide
positions -6 and +141 relative to the CCK mRNA translation
start site. The gastrin shRNA target site sequence started
at nucleoside position +286 on the gastrin mRNA. BLAST
analysis revealed no significant homologies between the
sequences and mRNAs other than human CCK or gastrin.
Non-specific shRNA control plasmids containing an shRNA
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Table I. CCK and gastrin shRNA target sequences.
–––––––––––––––––––––––––––––––––––––––––––––––––
Target site
Sequence
–––––––––––––––––––––––––––––––––––––––––––––––––
-6 CCK mRNA 5'-AAAGCCAUGAACAGCGGC-3'
+141 CCK mRNA 5'-CAGAGAACGGAUGGCGAGU-3'
+286 gastrin mRNA 5'-GUGCUGAGGAUGAGAACUA-3'
–––––––––––––––––––––––––––––––––––––––––––––––––
oligonucleotide duplex with no homology to any mammalian gene sequence (Oligoengine, Seattle, WA) served as a
control for general cellular responses to double-stranded
RNA. Annealed oligonucleotide duplexes were cloned into
the pSUPER vector (Oligoengine) containing a hygromycin
resistance gene for CCK clones and neomycin resistance
gene for gastrin clones for selection. Plasmid constructs
were transfected into BxPC-3 pancreatic cancer cells with
Lipofectamine 2000 (Invitrogen). At least 50 stable BxPC-3
clonal transfectants were selected for each of the shRNA
constructs. CCK and gastrin mRNA knockdown was assessed
by real-time RT-PCR. The generation of the BxPC-3 gastrin
knockdown clone sh286, which is also used in this study, has
been previously published (14).
Additionally, a full-length human CCK antisense cDNA
in vector pcDNA3.1(-) (Invitrogen) was transfected into
BxPC-3 pancreatic cancer cells using Lipofectamine 2000.
Control cells were treated with empty vector DNA. Stable
clones were selected and CCK mRNA knockdown was
confirmed by RT-PCR.
Measurement of CCK peptide in human pancreatic cancer
cells and clones by radioimmunoassay. BxPC-3 pancreatic
cancer cells and clones that had been stably transfected
with either non-specific shRNA, CCK shRNA (141 or -6),
antisense CCK DNA, or empty vector were grown in cell
culture to log-phase at which time the media were removed
and replaced with fresh media. After 24 h of further growth,
the cells were rinsed, scraped, and cellular extracts collected
in dH2O containing 1X Complete Mini protease inhibitor
(Roche, Indianapolis, IN). CCK peptide radioimmunoassay
was performed in duplicate using a RIA kit from ALPCO
Diagnostics (Windham, NH) with rabbit antiserum to synthetic
CCK 26-33, sulfate and 125I-BH CCK-8. This antibody has
0.5% cross reactivity to sulfated gastrin-17 and <0.01% cross
reactivity to non-sulfated gastrin-17. Samples were standardized by protein concentration using a Micro BCA protein
assay with albumin as standard (Pierce, Rockford, IL).
In vivo tumor growth. Athymic nude mice (Harlan, 6-week
male nu/nu) were used for in vivo tumor growth experiments.
The Institutional Animal Care and Usage Committee of the
Pennsylvania State University College of Medicine approved
the research protocol and animals were housed in accordance
with the AAALAC guidelines for veterinary medicine. BxPC-3
cells were harvested from culture flasks with trypsin, centrifuged and washed. Cells (1x106) were suspended in 0.1 ml of
Hank's buffered saline solution (HBSS) and injected subcutaneously into the right and left flanks of each mouse. Tumor
diameter was measured weekly with calipers and tumors
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were removed if the mean tumor diameter exceeded 12 mm. At
least 6 animals were analyzed for each of the following clones
(N=12 tumors per group): CCK shRNA -6, CCK shRNA +141,
non-specific shRNA control (NSC), or gastrin shRNA 286.
Statistical analysis. Real-time RT-PCR groups were compared
by ANOVA and pair wise t-tests with a Bonferroni correction
for multiple comparisons. Real-time RT-PCR results were
expressed as a relative quantity according to the method of
Livak and Schmittgen (19). In vivo tumor growth was analyzed
using pair wise Mann-Whitney tests on groups as indicated.
The data from each clone were pooled and analyzed using
mean values. Significance of two-sided statistical tests was
considered to be p<0.05.
Results
Quantification of CCK mRNA in human pancreatic adenocarcinoma cell lines. Pancreatic cancer cells were analyzed
for their endogenous expression of CCK peptide, gastrin
peptide, CCK1 receptor and CCK2 receptor mRNA by real-time
RT-PCR. CCK mRNA was detected in 4 of 5 human pancreatic
adenocarcinoma cell lines analyzed. Quantification of CCK
mRNA levels by real-time RT-PCR revealed that Capan-1
had high CCK mRNA levels (Fig. 1A). PANC-1, BxPC-3
and AsPC-1 expressed intermediate levels of CCK mRNA
and CCK mRNA from MIA PaCa-2 cells was undetected by
real-time RT-PCR; therefore MIA PaCa-2 cells were excluded
from the pool of potential cancer cells to examine autocrine
effects of CCK peptide.
Gastrin mRNA expression from the same cell lines is
shown in Fig. 1B revealing gastrin mRNA was detected at
levels that exceeded that of CCK peptide mRNA in all cell
lines except PANC-1 cell which had comparable levels. CCK1
receptor mRNA (Fig. 1C) was detected in PANC-1 and
Capan-1 cancer cells. All cancer cell lines examined had
detectable CCK2 receptor mRNA (Fig. 1D).
The presence and localization of intracellular CCK
peptide was examined by immunocytochemistry in wild-type
BxPC-3 cancer cells (Fig. 1E). CCK immunoreactivity was
found predominantly in the cytoplasm but slight nuclear
immunoreactivity was also observed. This pattern of staining
previously described by Tamiolakis and colleagues (17)
appears to be characteristic of CCK immunoreactivity.
Gastrin is a more potent stimulant of pancreatic cancer cell
proliferation. In BxPC-3 cancer cells, exogenous gastrin
application stimulated cell growth with concentrations of
gastrin that were 100-fold lower than the concentration of
CCK and with a more profound response (Fig. 2A). BxPC-3
cells grown in serum-free media alone (controls) underwent
3.5 doublings over a 6-day time period, while cells treated
with 10-9 M gastrin increased 68% over control cells (Fig. 2A).
In contrast, cells treated with CCK-8 only increased by 36%
over controls when treated with a concentration of CCK that
was 100-fold greater (10-7 M) than the gastrin concentration
which stimulated growth (Fig. 2B).
Decreasing CCK peptide levels with neutralizing CCK
antibodies has no effect on in vitro growth. To test the effect
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Figure 1. Quantification of CCK, gastrin, CCK1 receptor and CCK2 receptor mRNA expression in human pancreatic cancer cell lines by real-time RT-PCR.
Human cultured pancreatic cancer cell lines AsPC-1, BxPC-3, Capan-1, MIA PaCa2 and PANC-1 were analyzed for the expression of CCK mRNA (A),
gastrin mRNA (B), CCK1 receptor mRNA (C) and CCK2 receptor mRNA (D) by real-time RT-PCR. The presence of CCK peptide in BxPC-3 cells was
verified by immunocytochemical staining (E1) with an anti-CCK antibody. Cells were reacted with an anti-human CCK antibody followed by a goat antirabbit Alexa Fluor 568 labeled secondary antibody. Negative control cells (E2) were stained with secondary antibody alone. Asterisks (*p<0.05, **p<0.001)
indicate values significantly different from that in PANC-1 cells, which express all four gene products. N.C., not called.

Figure 2. Comparison of effects of exogenous gastrin or CCK on growth of BxPC-3 cells in vitro. Cells were grown in serum-free medium in the presence of
either CCK or gastrin (10-11-10-7 M) for 6 days, with fresh media with or without the indicated peptide added daily. Gastrin stimulated cancer cell growth
twice that of CCK at a 100-fold lower concentration of gastrin. Bars represent the standard error of the mean of 12 replicates. Significantly different from
controls *p<0.05.
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Figure 3. Effects of selective, neutralizing CCK antibodies on the growth of pancreatic cancer cells in vitro. Treatment of BxPC-3 cells with increasing
amounts of antibody against proCCK (A) or fully processed CCK (B) over the course of one week did not inhibit cell proliferation. PANC-1 cells treated with
varying concentrations of anti-CCK antibody (C2581) in serum-free media also grew at the same rate as untreated cells or as cells treated with a non-immune
IgG (C). Bars represent the standard error of the mean of 12 replicates. Significantly different from controls *p<0.05.

of reducing levels of endogenously produced CCK peptide
on in vitro growth of wild-type BxPC-3 cells, two neutralizing
CCK antibodies were used (Ab89009 and C2581). Neither
CCK antibody at dilutions of up to 1:500 had any effect cell
growth over a one-week period (Fig. 3A and B). There was
no effect on cell number when another pancreatic cancer cell
line, PANC-1 cancer cells, was treated with the CCK antibody, C2581 (1:500) compared to media alone or nonimmune IgG (Fig. 3C).
Down-regulation of CCK using RNAi. BxPC-3 was chosen as
the recipient cell line for CCK peptide down-regulation for
several reasons. First, this cell line has an intermediate level
of expression of both CCK and gastrin mRNA and expresses
only the CCK2 receptor (not the CCK1 receptor), which binds
both peptides equally. Second, it is known that the addition
of either gastrin (3) or CCK (2) peptide to culture media
stimulates BxPC-3 growth in vitro, indicating that this cell
line has a physiologically relevant response to both of these
peptides. Third, previous work with BxPC-3 cells showed
that this cell line contains levels of gastrin that are comparable
to those found in fresh human surgical pancreatic tumors,
making it a representative model for study (13). Thus, we
chose to use this cell line in order to make a direct comparison

of the growth effects of CCK knockdown to the growth
effects of gastrin knockdown.
Although CCK1 (CCK-A) receptors have previously been
described in pancreatic cancer tissues (20), the role and
significance of these receptors is unknown since CCKstimulated growth in pancreatic cancer is mediated through
the CCK2 receptor (5). Since CCK peptide binds to the CCK1
receptor with greater affinity (21) than the CCK2 receptor, we
specifically selected a cell line that lacked CCK1 receptors to
target only the CCK 2 receptor which is involved in cell
proliferation. Although PANC-1 and Capan-1 make more
CCK mRNA than BxPC-3, these cell lines were not chosen
for the down-regulation experiments for several additional
reasons. First, the effects of CCK or gastrin on growth of
Capan-1 in vitro or in vivo have not been described. Second,
PANC-1 and Capan-1 cells both express the CCK1 receptor
(Fig. 1); therefore, neither of these two cell lines were
selected for the transfection experiments to eliminate the offtarget effect. Use of selective CCK 1 and CCK 2 receptor
antagonists has demonstrated that the growth stimulation by
CCK (22) and gastrin (3) is mediated through the CCK2
receptor and that blockade of the CCK1 receptor does not
influence the growth rate of pancreatic cancer cells. Third,
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Figure 4. CCK mRNA levels in pancreatic cancer CCK down-regulated clones and controls. (A) Real-time RT-PCR analysis of BxPC-3 cells shows significantly less CCK mRNA in clones stably transfected with either of two different CCK shRNA constructs (shRNA -6 or shRNA +141) compared to a nonspecific control shRNA (NSC) or wild-type cells. Columns represent the fold change in mRNA levels calculated from the mean relative quantity (RQ = 2-ΔΔCT)
and bars represent a 95% confidence interval (CI; RQ = 2-(ΔΔCT±CI)). (B) Real-time RT-PCR for CCK mRNA in CCK antisense-transfected clones. Antisense
clones 6 and 10 had decreased CCK mRNA expression. Significantly different from untransfected control cells at *p<0.05, **p<0.001, or ***p<0.0001 or
specific p-values as noted.

the impact of gastrin knockdown on Capan-1 tumor growth
has not been assessed, so a direct comparison of the effects
of gastrin and CCK knockdown on tumor growth cannot be
made. For all these reasons, BxPC-3 cancer cells were
selected for the RNAi experiments.
Cholecystokinin mRNA expression was effectively
decreased with both antisense and shRNA transfection
(Fig. 4). Cells transfected with either the CCK shRNA -6 or
the shRNA +141 construct showed significant reduction in CCK
mRNA levels compared to non-specific (NSC)-transfected
control clones as assessed by real-time RT-PCR was performed. Compared to untransfected cells, CCK mRNA levels
in the CCK shRNA -6 and shRNA +141 clones were significantly decreased by 56% (**p<0.001) and 76% (***p<0.0001),
respectively (Fig. 4A). The non-specific shRNA clones had
slightly more CCK mRNA than untransfected, wild-type
cells thought to be due to clonal variation. Antisense downregulation of CCK mRNA was found in two BxPC-3 clones
(6 and 10) (Fig. 4B). These two antisense clones were selected
for further analysis of CCK peptide levels by RIA.
CCK peptide levels in pancreatic cancer cells and CCK
knockdown clones by radioimmunoassay. CCK peptide as
measured by RIA in cellular extracts was decreased by 60%
in CCK shRNA -6 clones compared to wild-type cells, whereas
the CCK shRNA +141 clones did not show a significant
decrease in CCK peptide (Table II). Both clones transfected
with the CCK antisense cDNA showed decreased CCK
peptide compared to controls, but the decreased peptide
expression was not as pronounced as that obtained with the
CCK RNAi using shRNA -6.
Influence of CCK and gastrin on tumor growth in vivo.
BxPC-3 clones with reduced CCK mRNA levels were tested

Table II. CCK peptide radioimmunoassay.
–––––––––––––––––––––––––––––––––––––––––––––––––
Cellular extracts of
CCK
BxPC-3 cells and clones
(pg/mg protein)
–––––––––––––––––––––––––––––––––––––––––––––––––
Wild-type
1.25
NSC shRNA (control)
1.07
Empty vector antisense (control)
1.36
CCK shRNA +141
1.64
CCK shRNA -6
0.50a
CCK antisense clone 10
0.91
CCK antisense clone 6
0.71a
–––––––––––––––––––––––––––––––––––––––––––––––––
ap<0.05

indicates values significantly different from that in wildtype BxPC-3 cells.

–––––––––––––––––––––––––––––––––––––––––––––––––

for their ability to form tumors in vivo. The rate of tumor
growth corresponded to the amount of CCK peptide detected
in the same cells by RIA (Fig. 5). The CCK shRNA +141
clone grew fastest and also had the greatest amount of CCK
peptide detected by RIA. The CCK shRNA -6 cells grew the
slowest of the CCK-down-regulated clones in animals and
this clone had the least amount of CCK peptide detected by
RIA. Although CCK mRNA levels were reduced in up to
76% in the CCK shRNA +141 clones, it appears that tumor
growth is more dependent upon post-transcriptional processing,
i.e., peptide levels. However, neither of the CCK-downregulated clones grew statistically different from the controls.
BxPC-3 cells with decreased gastrin expression developed
significantly smaller tumors over the 5-week period of time
(Fig. 5). The relationship between tumor growth at 5 weeks
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Figure 5. Down-regulation of gastrin but not CCK decreases tumor growth
of pancreatic cancer in vivo. Growth of BxPC-3 CCK knock-down clones
was measured as subcutaneous tumors in nude mice over five weeks. There
were no significant differences in tumor growth of BxPC-3 cells in which
CCK peptide was down-regulated compared to a non-specific control clone.
In contrast, tumors from a BxPC-3 gastrin knockdown clone were significantly smaller than any of the CCK shRNA clones or non-specific control
tumors. Significantly different from NSC *p<0.05.

and the corresponding gastrin and CCK mRNA levels in
these tumors is shown in Fig. 6. BxPC-3 cells with normal
gastrin and CCK mRNA levels formed large tumors in vivo
(Fig. 6). Conversely, when gastrin expression was decreased
without altering CCK expression, tumors were significantly
smaller. These results indicate that pancreatic tumor growth
is highly dependent on autocrine gastrin expression and that
the amount of endogenous CCK produced by BxPC-3 cells is
insufficient to maintain growth in the absence of gastrin.
Discussion
The current investigation is the first to report the quantification of endogenous CCK mRNA and peptide in human
pancreatic cancers and demonstrate the effect of downregulating CCK on tumor growth. Although conflicting
publications both support (17) and oppose (16) the presence
of endogenous CCK in human pancreatic cancer by immunohistochemistry, we demonstrate and confirm both the
presence and quantity of CCK mRNA and peptide in pancreatic
cancer by sensitive cellular and molecular techniques.
Autocrine gastrin and its receptors have been known to play
a role in proliferation of pancreatic cancer (3,23) but the role
of CCK has not been directly examined. In the current study,
we demonstrate that human pancreatic cancer cells produce
endogenous CCK; however, down-regulation of this peptide
does not affect tumor cell growth in vivo. In pancreatic
cancer cell lines that produce both peptides, gastrin is the
predominant autocrine peptide influencing cell growth.
The reasons why only autocrine gastrin and not CCK
seem to be important for pancreatic cancer growth may be
related to the amount of these peptides produced. In this
study, the amount of CCK peptide secreted by BxPC-3 cancer
cells and measured by RIA is considerably less (228-fold)
than that previously reported for gastrin (7). Perhaps the
lower levels of CCK peptide may account for the inability to
detect CCK immunoreactivity in pancreatic cancer specimens
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Figure 6. In vivo pancreatic tumor growth in mice is dependent on autocrine
gastrin but not autocrine CCK production. Subcutaneous tumors of wild-type
BxPC-3 cells which express both gastrin and CCK reached a mean tumor
diameter of 13.3 mm by week four. In BxPC-3 cells where only gastrin
mRNA was down-regulated and CCK mRNA was unaltered (right), tumors
were significantly smaller than wild-type tumors. Tumor size (mm) is shown in
the hatched columns. Significantly different from wild-type cells ***p<0.0001
and †p<0.00001.

examined by Goetze and colleagues (16). In view of the fact
that most of the pancreatic cancer cell lines examined thus
far secrete both gastrin (7) and CCK, it would be difficult
to evaluate whether CCK itself contributes at all to cell
proliferation since in the natural state gastrin appears to be
the more abundant and ubiquitous peptide. Furthermore,
since decreasing CCK does not alter tumor size, it is likely
that growth is stimulated by the continued proliferative action
of gastrin on the CCK2 receptor. In contrast, when gastrin is
down-regulated in BxPC-3 cells without altering CCK levels,
in vivo tumor growth is drastically reduced. These results
indicate that although endogenous CCK is produced by tumor
cells, this peptide is not adequate or sufficient to stimulate
tumor growth by itself. Our study clearly shows that although
the majority of human ductal pancreatic cancers produce
both peptides, gastrin is the dominant peptide responsible for
growth stimulation and tumor formation in vivo.
In this investigation, we also demonstrated that when the
cells are exposed to exogenous peptides, equimolar concentrations of gastrin are more potent in stimulating growth of
BxPC-3 pancreatic cancer cells than CCK. Previously we had
confirmed that the predominant CCK receptor responsible for
the proliferative actions of these peptides in pancreatic cancer
was the CCK2 receptor (4,7) or a spliced variant form of this
receptor which retains the forth intron (6). When competition
receptor binding assays were performed with either 125I-CCK
(22) or [H3]-L365,260 (a CCK 2 receptor antagonist), the
affinity for gastrin at the CCK2 receptor was 50-fold greater
than that for CCK (4,22). This increased affinity for gastrin
over CCK to the CCK2 receptor in malignant tissues is unlike
that reported for gastrin's at the CCK2 receptor in normal
tissues where CCK and gastrin possess equal binding affinity
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(Kd) (24) and may contribute to the greater effect demonstrated with gastrin.
The use of RNA interference (RNAi) technologies to
reduce the expression of disease-related genes is becoming
more widespread. Thus, a clear understanding of which gene
products are modified by RNAi regulation and which nucleotide residues within a particular mRNA are the best targets
for down-regulating gene expression is essential when developing new therapeutic agents. Because of their relatively
small size, the mRNAs encoding peptides such as CCK
and gastrin are especially amenable to regulation by RNAi
technologies. Since these peptides act as growth factors for
diseases such as pancreatic cancer, where few effective
treatments are available clinically, development and testing
of shRNAs targeting small peptides for cancer treatment is a
critical area of research. In this study, we have defined two
RNAi target sites within the human CCK mRNA that can
effectively reduce the levels of this mRNA. Although these
target sites will not be clinically relevant in the future
treatment of pancreatic cancer, they may be useful in downregulation of CCK in other tissues.
The effectiveness of the down-regulation of target site
may also be dependent on nucleotide position and secondary
mRNA structure as well as post-transcriptional and translational events. Little clonal variation was observed with our
shRNA transfections as compared to antisense techniques.
Furthermore, shRNA location differences were found in that
the shRNA +141 target site was more efficient in decreasing
CCK mRNA levels than was the CCK shRNA -6 target site
suggesting RNAi targeted close to the translation start site is
less effective (25). Others have shown that the secondary
structure of the mRNA target is the most critical factor in
RNAi design (26). However, the results from the RIA in this
report indicated post-transcriptional modifications affect the
quantity of peptide produced which may be more important
than the amount of mRNA available. Therefore, although the
shRNA +141 clones had less mRNA, the peptide production
and tumor growth was decreased more with the shRNA -6
target site.
Another possible explanation for why significant CCK
peptide down-regulation did not alter growth in pancreatic
cancer may be that CCK mRNA is very stable or preferentially translated in order to maintain CCK peptides levels.
This idea is unlikely since it is in conflict with other reports
of concurrent mRNA and protein knockdown using a similar
plasmid-based shRNA system with BxPC-3 cells. Wei et al
recently reported that an shRNA directed against the Mcl-1
mRNA reduced both Mcl-1 mRNA and protein levels by
60-70% in BxPC-3, PANC-1 and SW1990 (27). The Mcl-1
shRNA expressing cells also formed smaller tumors than
untransfected cells or vector-only and non-specific shRNA
controls.
The current report confirms the expression of CCK
peptide or mRNA in pancreatic cancer (17) and is the first
report documenting the use of RNAi technology to downregulate CCK in this cancer. Our study validates two novel
RNAi targets sites within the CCK mRNA: the mRNA
sequences beginning at nucleotide -6 and at nucleotide +141.
Although a significant decrease in CCK mRNA was clearly
achieved by these shRNA constructs, their utility in decreasing

tumor growth in pancreatic cancer cells was not demonstrated
most likely due to concomitant gastrin production. Using an
shRNA to CCK mRNA in Ewing's tumors, Carrillo et al (28)
were able to demonstrate >90% down-regulation of CCK by
real-time RT-PCR as well as decreased peptide secretion by
RIA. Unfortunately, similar to our results, this group found
that in spite of significant CCK suppression, tumor xenografts
still grew well in nude mice suggesting growth factors other
than CCK play an important role. We conclude that CCK can
be efficiently down-regulated, but RNAi therapeutics that
target gastrin would be a better strategy for pancreatic cancer
treatment.
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